Delivery of a BET Protein Degrader via a CEACAM6-Targeted Antibody–Drug Conjugate Inhibits Tumor Growth in Pancreatic Cancer Models

To improve PDAC therapy, researchers established screening systems based on organoid and co-culture technologies and found a payload of antibody–drug conjugate, a bromodomain and extra-terminal (BET) protein degrader named EBET.